The U.S. Food and Drug Administration issued final technical specifications in May 2026 for submitting continuous glucose monitoring data in clinical trials that support marketing applications for drugs and biological products.
The document is especially relevant to metabolic and diabetes research programs that use continuous glucose monitoring as a source of high-frequency clinical data or as part of trial endpoint analysis.
Standardizing high-frequency glucose data
Continuous glucose monitors can generate large volumes of timestamped data across a clinical trial. FDA's technical specifications are intended to create a more consistent structure for submitting those data so reviewers can understand how individual readings flow into analysis datasets and study endpoints.
The document describes specifications for standardized datasets, device-level information, analysis variables, data completeness, and traceability between source data and derived analyses.
Time, missing data, and traceability matter
FDA specifically notes the importance of using complete timestamps, including hours, minutes, and seconds, when assigning epoch-level CGM readings to analysis windows. The document also addresses how missing readings and reasons for missing data may be represented in submitted datasets.
These details matter because CGM studies may depend on thousands of individual observations rather than a small number of measurements collected during scheduled clinic visits.
Operational relevance for metabolic trials
Although the technical specifications are primarily focused on regulatory submission datasets, they also reinforce the need for strong upstream operational controls. Device assignment, participant training, wear periods, data transfer, troubleshooting, timestamps, and documentation can all affect the completeness and interpretability of the final dataset.
For sites participating in diabetes and metabolic studies, clear study-specific workflows around CGM technology remain an important part of reliable trial execution.